Feasibility of Aldosterone Synthase Inhibitor for the Treatment of Primary Aldosteronism:Viewpoint
10.3969/j.issn.1000-3614.2024.09.014
- VernacularTitle:醛固酮合成酶抑制剂治疗原发性醛固酮增多症的可行性探讨
- Author:
Hui DONG
1
;
Yujie ZUO
;
Xiongjing JIANG
Author Information
1. 中国医学科学院 北京协和医学院 国家心血管病中心 阜外医院 心内科,北京 100037
- Keywords:
primary aldosteronism;
aldosterone synthase inhibitor;
aldosterone
- From:
Chinese Circulation Journal
2024;39(9):920-923
- CountryChina
- Language:Chinese
-
Abstract:
In recent years,aldosterone synthase inhibitor(ASI)has attracted widespread attention as a treatment option for hypertension.Drugs such as osilodrostat,baxdrostat,lorundrostat,and dexfadrostat have been developed and the therapeutic effects have been evaluated in a series of clinical studies.This article intends to elaborate current clinical research results,problems,and controversies of ASI for the treatment of hypertension,and explore the feasibility of using ASI for the treatment of primary aldosteronism.
